CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI) Proteomics to Improve Phenotyping in Obese Patients with Heart Failure with Preserved Ejection Fraction Noninvasive Imaging for the Evaluation of Diastolic Function: Promises Fulfilled Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy JACC Guideline Comparison: JACC State-of-the-Art Review Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) Trial Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes Transcatheter Aortic Valve Implantation Represents an Anti-Inflammatory Therapy Via Reduction of Shear Stress-Induced, Piezo-1-Mediated Monocyte Activation Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial

Clinical Trial2013 Dec 18;310(23):2510-22.

JOURNAL:JAMA. Article Link

Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial

Feres F, Costa RA, OPTIMIZE Trial Investigators. Keywords: DAPT duration; Dual antiplatelet therapy (DAPT); DES; bleeding; coronary stenting

FULL TEXT PDF